ethylmethylhydroxypyridine-succinate and Parkinson-Disease

The efficiency of mexidant therapy in patients with Parkinson's disease (PD) has been evaluated. The study included 49 patients aged 58-65 with a trembling-rigid and trembling forms of PD at an disease duration of 6.5 +/- 3.8 years. All patients were treated with levadopa-containing drugs, dopamine receptor agonists and/or amantadine. In addition, 27 patients received mexidant at a dose of 200 mg/day (i.v.) for the first 10 days, followed by intramuscular injections of 100 mg (twice a day) for 10 days. The dynamics of symptoms in the group of patients receiving mexidat showed that the inclusion of this drug into the therapeutic regime significantly decreased the degree of levadopa therapy side effects. Mexidant reduced the oxidative damages of blood plasma lipoproteins by neutralizing the growth of lipid hydroperoxide and increased the endogenous antioxidant status. The presented data show that mexidant enhances the efficiency of PD therapy.

Topics: Aged; Amantadine; Antioxidants; Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Levodopa; Lipid Peroxidation; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Pyridines